All In Biotech

BLA 021018 · Lilly

Humalog Mix 50/50 Kwikpen

Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant · Injection · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Jul 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 22, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

123,775

59,244 serious, 5,612 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 27, 2026.

HUMALOG Mix50/50 is indicated to improve glycemic control in adults with diabetes mellitus. HUMALOG ® Mix50/50™ is a mixture of insulin lispro protamine, an intermediate-acting human insulin analog, and insulin lispro, a rapid-acting human insulin analog, indicated to improve glycemic control in adults with diabetes mellitus. ( 1 ) Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. ( 1 ) Limitations of Use The proportions of rapid-acting and intermediate-acting insulins in HUMALOG Mix50/50 are fixed and do not allow for basal versus prandial dose adjustments.

Mechanism: The primary activity of insulin including HUMALOG Mix50/50 is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1999 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LetterReviewLabel
3 products under this application
  • HUMALOG MIX 50/50 KWIKPEN · INSULIN LISPRO PROTAMINE RECOMBINANT 50 UNITS/ML; INSULIN LISPRO RECOMBINANT 50 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HUMALOG MIX 50/50 PEN · INSULIN LISPRO PROTAMINE RECOMBINANT 50 UNITS/ML; INSULIN LISPRO RECOMBINANT 50 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HUMALOG MIX 50/50 · INSULIN LISPRO PROTAMINE RECOMBINANT 50 UNITS/ML; INSULIN LISPRO RECOMBINANT 50 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro Protamine Recombinant" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased34,684
  • blood glucose decreased8,066
  • incorrect dose administered7,997
  • drug ineffective7,527
  • visual impairment4,804
  • nausea4,696
  • malaise3,657
  • hypoglycaemia3,632
  • fatigue3,581
  • fall3,258
  • drug dose omission3,241
  • vomiting3,118

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,188
20051,265
20061,680
20071,554
20081,463
20091,792
20101,836
20112,030
20122,096
20131,703
20144,546
201524,696
20168,366
20178,084
20188,473
20198,512
20208,710
20217,308
20226,399
20235,579
20245,212
20257,616
20263,667

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humalog Mix 50-50 (Insulin Lispro Protamin/Lispro)

2024 spending

$24K

Beneficiaries

108

131 claims

Per beneficiary

$219

$7.96 per unit

View as table
YearSpending
2020$10,144,997
2021$9,337,859
2022$8,094,938
2023$6,085,553
2024$23,627

Part D: Humalog Mix 50-50 Kwikpen (Insulin Lispro Protamin/Lispro)

2024 spending

$6.1M

Beneficiaries

4,267

18,627 claims

Per beneficiary

$1,431

$9.96 per unit

View as table
YearSpending
2020$24,113,084
2021$22,618,250
2022$20,642,853
2023$20,294,452
2024$6,107,917

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Eli Lilly · Also marketed as Humalog Mix 50/50 Pen, Humalog Mix 50/50

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.